The Next Wave of HealthTech Unicorns and Soonicorns in Europe and USA

Lloyd Price
Aug 5
17 min read

Executive Summary

The global health technology (healthtech) sector is undergoing a profound transformation, marked by a resurgence in investment and a strategic pivot towards artificial intelligence (AI) driven solutions. This report provides a comprehensive analysis of the healthtech landscape in Europe and the USA, identifying key "Soonicorns"— startups valued between $500 Million and $1 Billion, that are poised to achieve unicorn status ($1 Billion valuation) in 2025 or 2026.

The analysis highlights strategic growth areas such as AI-powered diagnostics, advanced drug discovery, and solutions enhancing operational efficiency within healthcare systems. While global digital health funding has seen a slight decline in overall volume, a deeper examination reveals a discerning investment climate characterised by larger, more targeted investments in late-stage companies leveraging AI. This shift underscores a market demand for proven, scalable innovations capable of delivering tangible value and addressing critical healthcare challenges.

Understanding Soonicorns and Unicorns in HealthTech

Defining the Tiers of Startup Valuation

The startup ecosystem employs specific terminology to categorise companies based on their valuation milestones, reflecting their growth trajectory and market potential.

Soonicorns: These are emerging startups that have achieved a valuation of $500 million and are actively "on the verge of achieving $1 Billion". A notable characteristic of soonicorns is that their valuations are frequently driven by future projections and estimated potential, which can sometimes exceed their immediate net worth. This implies that a substantial portion of their perceived value is tied to anticipated future performance and market capture, rather than solely on current revenue or existing assets.

For investors, this signifies that while soonicorns offer high-growth opportunities, the investment inherently carries a speculative premium. Consequently, thorough due diligence must extend beyond current financial metrics to rigorously scrutinize the viability of their business model, the realism of market forecasts, and their capacity to execute rapid growth plans to justify this forward-looking valuation. These companies typically exhibit rapidly expanding business models, reaching more customers and experiencing swift growth.

Unicorns: This widely recognised term refers to startups that have reached or exceeded a valuation of $1 Billion or more, as determined by venture capital funding. Achieving unicorn status is a significant milestone, often signalling market leadership, substantial traction, and a validated business model.

Current Global HealthTech Investment Climate (2025)

The digital health sector is navigating a complex yet dynamic investment landscape. While total global digital health funding in the first half of 2025 experienced a 13% year-over-year (YoY) decline, amounting to $12.1 Billion across 616 deals, this indicates a more discerning investment climate rather than a retreat. This trend is accompanied by a significant shift in capital allocation, with a notable increase in the average deal size, which grew to $26.1 Million in H1 2025, up from $20.4 Million in 2025 This growth in average deal size is primarily "spurred by larger investments in later-stage rounds (series B-D) as well as the bolstering impact of AI".

Artificial intelligence (AI)-enabled startups are the primary beneficiaries of this capital flow, capturing a remarkable 62% of venture capital dollars, totaling $3.95 Billion, in H1 2025. This represents a sharp increase from 41% in 2024. Furthermore, AI driven companies accounted for nine out of the eleven mega-deals (fundraises exceeding $100 Million) in H1 2025, underscoring their attractiveness to large institutional investors. This concentration of capital in AI-enabled ventures is a clear signal of market confidence in their transformative potential. Unicorn creation has also shown signs of rebound, with six new unicorns emerging in Q1 2025, a figure that surpasses the total number of unicorns created throughout all of 2024.

The seemingly contradictory trends of declining overall deal volume but increasing average deal size and a surge in AI-focused mega-rounds reveal a "selective scale" funding model. Investors are not withdrawing from healthtech; rather, they are becoming more risk-averse and strategic. They are consolidating capital into fewer, larger bets on companies that have demonstrated strong traction, clear technological differentiation, especially with AI and a viable path to profitability. The significant premium paid for AI enabled startups, with an average of $34.4 Million per round compared to $18.8 million for their non-AI counterparts , suggests that AI is viewed as a de-risking factor, promising "meaningful efficiency, margin, and scale gains". For soonicorns, this environment means that securing the final funding rounds to achieve unicorn status will necessitate robust evidence of market fit, strong unit economics and a compelling narrative around how AI is integral to their sustained growth and competitive advantage. Companies without a clear AI strategy or demonstrable scale may find it increasingly challenging to attract significant late-stage capital.

Europe's Ascending HealthTech Soonicorns

Overview of the European Healthtech Ecosystem

Europe's digital health innovation scene, historically overshadowed by the more robust ecosystems of Silicon Valley and Asia Pacific, is now presenting a compelling picture of growth and maturity. The region experienced a significant rebound in healthtech funding in the first half of 2025, reaching €6.21 Billion across various funding types, a notable increase from the €4.79 Million recorded in H2 2024. This resurgence is indicative of a maturing market and growing investor confidence.

Key sectors attracting this capital include Drug Discovery, which secured €2.34 Billion, and Medtech, which drew €1.89 Billion. Digital health funding, in particular, witnessed a remarkable 221% increase in H1 2025 compared to the same period last year. AI is a dominant force across these sectors, with approximately 60% of 2025 EU funding directed towards AI-driven health ventures.

A unique aspect of the European landscape is the strategic blend of private venture capital and substantial public funding programs. Initiatives such as Horizon Europe (with a €95.5 Billion budget), the EIC Accelerator (offering up to €2.5 Million in grants plus €15 Million in equity), EU4Health (€4.4 Billion for digital infrastructure and health data) and the Digital Europe Programme (targeting AI and cybersecurity adoption) provide significant support. These EU-level programs are complemented by national innovation agencies like Bpifrance in France (over €2.3 Billion deployed into health innovation since 2021), High-Tech Gründerfonds (HTGF) in Germany (€1.4 Billion AUM), and Innovate UK in the UK (Smart Grants up to £2 Million).

This public-private funding synergy provides European soonicorns with a more stable and potentially longer runway for development, particularly in deep tech areas such as drug discovery and complex medical diagnostics that require extensive research and development. This model also suggests that European healthtech companies may be more adept at navigating complex regulatory and reimbursement pathways, which are often intrinsically linked to public health initiatives and national healthcare systems.

Leading European HealthTech Soonicorns and High-Potential Candidates (2025-2026)

Company Name	Country	Primary Focus	Latest Funding Round (Amount & Date)	Latest Known Valuation	Key Investors
Huma	UK	AI-powered healthcare apps, digital health platforms	$80M (July 2024)	€928.3M (2024)	AstraZeneca, Bayer
Verdiva Bio	UK/US	Obesity and cardiometabolic therapies	$411M Series A (Jan 2025)	Not explicitly stated, likely >$500M	Forbion, General Atlantic, RA Capital Management, OrbiMed, Lilly Asia Ventures, LYFE Capital
Amboss	Germany	AI-driven medical knowledge platform, clinical decision support	€240M (March 2025)	~$282.9M total investments, likely >€500M post-round	KIRKBI, M&G Investments, Lightrock, Partech Ventures, Wellington Partners, HV Capital, Target Global, Cherry Ventures

Huma (UK): Huma leverages generative AI to accelerate and reduce the costs associated with developing healthcare applications. Its technology is extensively adopted, serving over 3,000 hospitals and clinics globally with 1.8 million active users across its various products. The company's business model focuses on industry-specific AI within the healthcare sector, positioning it as a leader in remote patient monitoring and digital health platforms. Huma reported a post-money valuation of €928.3 Million in 2024, placing it firmly within the soonicorn category. It secured $80 Million in funding in July 2024 from strategic investors, including pharmaceutical giants AstraZeneca and Bayer.

The direct investment from major pharmaceutical companies like AstraZeneca and Bayer into Huma signifies more than just financial backing; it indicates a strategic alignment where pharma companies view digital health platforms as crucial for enhancing drug efficacy, improving patient adherence, and potentially streamlining clinical trials or post-market surveillance. Huma's ability to attract such strategic investors suggests its platform is considered a critical enabler for future pharmaceutical strategies, providing strong validation of its business model and accelerating its path to unicorn status through deep integration into the healthcare value chain.

Verdiva Bio (UK/US): Verdiva Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and other cardiometabolic disorders. The company is advancing a portfolio of "next-generation oral and injectable treatments" with the potential for first-in-class or best-in-class efficacy, leveraging emerging science in gut-brain biology. Verdiva Bio launched with an oversubscribed Series A financing of $411 Million in January 2025. While an explicit post-money valuation for this round is not provided, a Series A round of this magnitude strongly indicates a valuation well into the soonicorn range, if not already exceeding $1 Billion.

The company's massive Series A funding directly correlates with the "lucrative opportunity for VCs since the arrival of new drugs such as Ozempic and Wegovy". This demonstrates a strong market pull and investor confidence in the long-term growth of the weight loss and cardiometabolic drug market. Verdiva Bio is strategically positioned to become a major player in a rapidly expanding therapeutic area, with its significant early-stage funding providing the capital runway necessary for extensive clinical development, which, if successful, could quickly propel it to unicorn status and beyond.

Amboss (Germany): Amboss is a global medical knowledge platform that digitally empowers physicians by integrating the latest medical content with cutting-edge AI technology. It functions as a "digital co-pilot" for clinical practice, providing precise and actionable recommendations for diagnostics and treatment. The platform is widely used, with over 1 Million users across more than 180 countries, and is particularly popular among US medical students for exam preparation. Amboss has strategically expanded its offerings through acquisitions, including Novaheal (nursing field) and NEJM Knowledge+ (US board exam prep).

The company closed a €240 Million financing round in March 2025. While a specific post-money valuation for this round is not explicitly stated, its total investments received are reported as $282.9 Million. A funding round of this size positions Amboss as a strong candidate for soonicorn status, given its established user base and market penetration. New long-term investors include KIRKBI, M&G Investments, and Lightrock, with continued participation from existing shareholders such as Partech Ventures, Wellington Partners, HV Capital, Target Global, and Cherry Ventures.

This substantial funding underscores investor belief in AI's transformative role in medical education and clinical practice. The company's emphasis on "responsible use of AI" and "rigorous validation" addresses critical concerns regarding AI adoption in sensitive healthcare contexts. Its widespread adoption by medical students and practitioners suggests it is becoming a foundational tool. By providing a trusted, AI-powered source of medical knowledge and decision support, Amboss is positioned to become indispensable infrastructure for healthcare professionals globally, with its ability to improve diagnostic accuracy, reduce errors, and streamline workflows providing a clear path to sustained growth and potential unicorn status.

USA's Next Wave of HealthTech Unicorns

Overview of the US Healthtech Ecosystem

The United States continues to lead the global digital health ecosystem in terms of funding, demonstrating resilience with a 4% year-over-year (YoY) increase in venture capital funding in 2024, reaching $17.2 Billion. This growth effectively halted a previous downward trend in investment. AI remains central to US digital health innovation, capturing a significant 58% of total funding in 2024. This underscores the US market's role as a proving ground for advanced AI applications in healthcare, where substantial capital is deployed to scale cutting-edge solutions.

Top-funded therapeutic areas in the US in 2024 included Oncology, attracting $2.44 Billion, and Mental Health, with $1.94 Billion in investment, reflecting significant strategic investment in these high-impact sectors. The US has also contributed significantly to the rebound in unicorn creation, producing four new unicorns in Q1 2025 alone. The sheer volume of funding, the dominant share of AI investment, and the consistent emergence of new unicorns in the US indicate that the US market acts as a dynamic crucible for healthtech innovation. It is here that AI driven solutions are rapidly developed, scaled, and validated, often attracting the largest capital injections. US healthtech soonicorns are therefore likely to be characterised by aggressive growth strategies, deep integration of AI across their offerings, and a strong focus on high-value, high-impact problem areas within the healthcare system. Their success often sets global benchmarks for the industry.

Leading US Healthtech Soonicorns and High-Potential Candidates (2025-2026)

Company Name	Country	Primary Focus	Latest Funding Round (Amount & Date)	Latest Known Valuation	Key Investors
Orbital Therapeutics	US	AI-driven RNA-based medicines	$270M Series A (Apr 2023)	$701.50M	Arch Venture Partners, Redmile Group, Casdin Capital, a16z, Newpath Partners
Tennr	US	AI for healthcare document intelligence, patient referrals	$101M Series C (Jun 2025)	~$605M (estimated from snippet typo)	IVP, Andreessen Horowitz, Lightspeed, GV, ICONIQ, Foundation Capital, Frank Slootman
Aidoc	US/Israel	AI for real-time clinical decisions, clinical foundation models	$150M (Jul 2025)	Valuation higher than previous round (total funding $370M)	General Catalyst, Square Peg, NVentures (NVIDIA), Sutter Health, Hartford HealthCare, Mercy, WellSpan Health
Commure	US	Full-stack AI platform for RCM, clinical workflows, practice management	$200M Series E (Jun 2025)	Not explicitly stated	General Catalyst's Customer Value Fund
Qventus	US	AI for hospital operations optimization	$105M Series D (Jan 2025)	Not explicitly stated	KKR, Bessemer Venture Partners, Mayfield, Norwest Venture Partners, Thomas H Lee Partners
Atomwise	US	AI-driven drug discovery	$157.04M Series C (Mar 2024)	$278.52M (total funding $483.04M)	DCVC, B Capital, Monsanto, Gates Foundation, Runway

Orbital Therapeutics (US): Orbital Therapeutics is an AI-driven RNA-based medicine company focused on the distribution and development of RNA medicines. This positions it within the high-growth "TechBio" and "Synthetic Biology" sectors, which are attracting significant investment. The company secured $270 Million in Series A funding in April 2023, achieving a post-money valuation of $701.50 Million, clearly positioning it as a soonicorn. Key investors include Arch Venture Partners, Redmile Group, Casdin Capital, a16z and Newpath Partners. The substantial Series A funding and its valuation highlight the significant investor confidence in RNA-based medicines. The integration of AI into this field suggests a belief in accelerating discovery and development, aligning with broader trends in AI-powered drug discovery. As precision medicine advances, companies like Orbital Therapeutics, which combine cutting-edge biological science with AI, are poised to develop transformative therapies. Their success could unlock new treatment modalities and significantly impact patient care, making them prime candidates for unicorn status.

Tennr (US): Tennr specialises in healthcare document intelligence, utilising proprietary AI document analysis tools to streamline and organise complex medical documents, particularly patient referrals. Its "RaeLM" (specialised language models) are specifically trained to understand the nuances of medical documentation, evaluate documents against complex payer criteria to flag potential denials, and have already helped process millions of patients across hundreds of providers. The company raised $101 Million in a Series C round in June 2025. While a snippet mentions a valuation of "$605 Billion", this is a clear typographical error; given the round size, this should be interpreted as $605 Million, placing it squarely in the soonicorn category. Tennr has also "more than tripled its revenue since its Series B just two quarters ago" , indicating rapid growth. Key investors include IVP, Andreessen Horowitz, Lightspeed, GV, ICONIQ, Foundation Capital, and Frank Slootman. Tennr's rapid revenue growth and substantial Series C funding for an AI solution focused on patient referrals highlight a critical pain point in healthcare: administrative inefficiencies that often lead to "patients get lost". This aligns with the top-funded digital health value propositions of "non-clinical workflow" and "clinical workflow". By automating and optimising complex, often paper-based, administrative tasks like referral processing, Tennr can significantly improve operational efficiency, reduce costs and enhance patient access within healthcare systems. Its ability to deliver tangible improvements in a high-volume area positions it as a strong contender for unicorn status.

Aidoc (US/Israel): Aidoc is an AI company focused on assisting medical teams with real-time clinical decisions. It provides AI-powered tools across radiology, cardiology, neurovascular, and vascular, with plans to expand into oncology. A major development is its clinical-grade foundation model, CARE, which underpins FDA-cleared AI products. Aidoc secured $150 Million in financing in July 2025, including $40 Million in a revolving credit facility. This brings its total funding to $370 Million. While no explicit post-money valuation for this latest round is provided, the funding was at a "valuation higher than its previous round", strongly suggesting it is in or near the soonicorn range. Key investors include General Catalyst, Square Peg, NVentures (NVIDIA's venture capital arm), and strategic investors from major U.S. health systems including Sutter Health, Hartford HealthCare, Mercy, and WellSpan Health. Aidoc's significant funding, particularly from NVIDIA's venture arm and major US health systems, highlights a critical shift towards clinical AI foundation models. This is not merely about providing AI tools but about building core AI infrastructure for healthcare. The involvement of health systems as strategic investors indicates a strong validation of Aidoc's technology and its potential for real-world impact and adoption. Aidoc is positioned to become a foundational technology provider in clinical AI. Its ability to secure investment from both tech giants and healthcare providers suggests a robust strategy for market penetration and a clear path to unicorn status by becoming indispensable for advanced clinical decision-making.

Commure (US): Commure offers a full-stack AI platform designed to accelerate healthcare transformation, encompassing revenue cycle management (RCM), Ambient AI clinical workflows, and practice management solutions. Its solutions aim to streamline operations and enhance efficiency for healthcare providers. The company raised $200 Million in growth financing (Series E) in June 2025 from General Catalyst's Customer Value Fund. While an explicit post-money valuation is not provided, a Series E round of this size for an AI platform in a high-demand sector strongly indicates a valuation within the soonicorn range. The key investor is General Catalyst's Customer Value Fund. Commure's substantial Series E funding for its AI platform, particularly its focus on RCM and clinical workflows, aligns with the significant investor interest in "non-clinical workflow" and "clinical workflow" AI solutions, which collectively drew over half of overall digital health funding in H1 2025.5 This indicates a recognition of the immense financial and operational challenges in healthcare. By providing AI-powered solutions that directly impact healthcare organisations' financial health and operational efficiency, Commure is addressing critical needs. Its ability to deliver tangible return on investment in these areas positions it to become a vital partner for healthcare systems, driving its growth towards unicorn status.

Qventus (US): Qventus provides AI-based software designed to optimise hospital operations. The company has developed "AI Operational Assistants" to reduce administrative burdens on care teams. Its solutions focus on improving resource utilisation and patient time optimisation within hospital settings. Qventus also provided pro bono support for the White House Task Force during COVID-19, aiding in ventilator placement predictions, which further validates its impact. Qventus has raised a total of $201 Million over six funding rounds. Its latest funding was a Series D round of $105 Million in January 2025, led by KKR. While an explicit post-money valuation is not provided, a Series D round of this size for an AI-driven operational platform suggests a valuation that is either in the soonicorn range or rapidly approaching it. Key investors include KKR, Bessemer Venture Partners, Mayfield, Norwest Venture Partners, and Thomas H Lee Partners. Qventus's continued success in securing large funding rounds for AI-driven hospital operations reflects the urgent need for healthcare systems to improve efficiency, reduce costs, and address workforce shortages. Its demonstrable impact during the pandemic further validates its value proposition. As hospitals face increasing pressures, solutions like Qventus that can optimize complex workflows and resource allocation through AI are becoming indispensable. Its ability to deliver measurable improvements in operational performance positions it to become a critical infrastructure provider, driving its path to unicorn status.

Atomwise (US): Atomwise is a company focused on AI-driven drug discovery, specifically providing a structure-based drug designing platform using AI. It aims to develop superior medicines more quickly. The company has raised a total funding of $483.04 Million to date. Its latest funding was a Series C round of $157.04 Million in March 2024, at a post-money valuation of $278.52 Million. While this valuation is currently below the $500 Million soonicorn threshold, its substantial total funding, recent large round, and position in the highly strategic AI drug discovery sector (a top-funded area) make it a high-potential candidate for soonicorn status in the near future. Key investors include DCVC, B Capital, Monsanto, Gates Foundation, and Runway. Atomwise's significant total funding and its focus on AI-driven drug discovery highlight the transformative potential of AI in accelerating and de-risking the drug development pipeline. This aligns with the broader trend of "TechBio" attracting substantial investment. By leveraging AI to identify and design new drug candidates more efficiently, Atomwise is positioned to significantly reduce the time and cost associated with bringing new therapies to market. Its success could lead to breakthroughs in various disease areas, making it a strong contender for rapid growth and eventual unicorn status.

Key Trends Shaping HealthTech Soonicorn Growth

The Pervasive Influence of AI and Generative AI

Artificial intelligence is not merely a transient trend but a foundational technology that is fundamentally reshaping healthcare delivery across multiple domains. It is driving advancements in "research solutions, precision diagnostics, and patient-centric health management". The financial data unequivocally supports AI's dominance in the healthtech investment landscape: AI-enabled startups captured a substantial 62% of venture capital funding in H1 2025 and accounted for the majority of mega-deals (nine out of eleven in H1 2025). This overwhelming proportion of funding directed towards AI-enabled startups, particularly in large, late-stage rounds, indicates a fundamental shift in investor perception. AI is no longer a supplementary feature but is increasingly seen as the core engine driving a healthtech company's value proposition, scalability, and competitive differentiation. Companies are not just using AI; they are fundamentally built on AI. Key applications of AI include accelerating drug discovery, enhancing clinical trial efficiency solutions, and streamlining operational functions within healthcare systems. For healthtech soonicorns, this means they must demonstrate how AI is deeply embedded in their core product or service, delivering measurable improvements in efficiency, accuracy, or patient outcomes. Companies that can articulate a clear "AI-first" strategy and show tangible results will be prioritised for future investment and market leadership.

Focus on Research Solutions and Medical Diagnostics

These areas consistently emerge as dominant clusters in healthtech innovation, reflecting a strategic industry-wide push towards more precise, personalised, and proactive healthcare. In Europe, Oncology and Women's Health lead therapeutic areas, with Research Solutions (often referred to as TechBio) and Medical Diagnostics claiming significant representation in the HealthTech 250. Globally, these clusters remain key innovation hubs, with Research Solutions accounting for 16% and Medical Diagnostics for 15% of selected ventures. In the US, Oncology ($2.44 Billion) and Mental Health ($1.94 Billion) were the top-funded therapeutic areas in 2024. The sustained investment in these fields highlights a broader industry push towards more precise, personalised and proactive care, where early and accurate diagnosis is critical. AI is particularly transformative in these areas, enhancing accuracy and efficiency in medical imaging, genomics and pathology, and expanding access to underserved populations through remote and cloud-based solutions. This focus on precision and proactive care offers high impact and strong return on investment for investors, as these solutions directly address the escalating costs and complexities of modern healthcare.

Conclusion

The healthtech market is currently characterised by dynamic shifts, with investment capital increasingly flowing towards companies that demonstrate clear value proposition, scalability, and a deep integration of artificial intelligence. Soonicorns, defined by their $500 Million to $1 Billion valuation and rapid growth, represent the vanguard of this transformation.

In Europe, a unique public-private funding synergy provides a stable foundation for healthtech innovation, particularly in deep tech areas like drug discovery and complex diagnostics. Companies such as Huma, Verdiva Bio, and Amboss exemplify this trend, leveraging AI to enhance digital health platforms, develop next-generation therapies, and revolutionise medical knowledge dissemination. Their ability to attract significant capital from both traditional venture firms and strategic corporate investors underscores the market's confidence in their potential.

Across the Atlantic, the US market continues to serve as an AI-driven innovation crucible, characterised by aggressive growth strategies and a strong focus on high-value problem areas. US soonicorns like Orbital Therapeutics, Tennr, Aidoc, Commure, Qventus, and Atomwise are at the forefront of this evolution. They are applying AI to accelerate RNA-based medicine development, streamline administrative bottlenecks, enhance clinical decision-making, optimise hospital operations, and disrupt pharmaceutical research and development. The substantial investments in these companies reflect a market belief that AI is not just a tool but the core engine for future healthcare efficiency, personalised medicine, and improved patient outcomes.

The overarching trend indicates a discerning investment climate where capital is concentrated in fewer, larger bets on companies with proven models and compelling AI strategies. For aspiring unicorns, demonstrating tangible impact, robust unit economics, and a clear path to scale through AI will be paramount. These soonicorns are not merely valuation milestones; they are indicators of fundamental shifts in healthcare delivery, with their AI-driven solutions addressing critical pain points and promising significant future impact on global health.

Nelson Advisors > Healthcare Technology M&A

Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide #Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech